Novel effect of antihelminthic niclosamide on s100a4-mediated metastatic progression in colon cancer

Journal of the National Cancer Institute

Volumn 103, Issue 13, 2011, Pages 1018-1036

  Sack, Ulrike ^a   Walther, Wolfgang ^b   Scudiero, Dominic ^c   Selby, Mike ^c   Kobelt, Dennis ^a   Lemm, Margit ^a   Fichtner, Iduna ^a   Schlag, Peter M ^b   Shoemaker, Robert H ^c   Stein, Ulrike ^b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CALVASCULIN; LUCIFERASE; MESSENGER RNA; NICLOSAMIDE; NICLOSAMIDE DERIVATIVE; SOLVENT; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL ANCHORAGE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; COLONY FORMATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER METASTASIS; LUMINESCENCE; METASTASIS INHIBITION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TUMOR XENOGRAFT;

ANIMALS; ANTHELMINTICS; ANTINEOPLASTIC AGENTS; BETA CATENIN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COLONIC NEOPLASMS; DISEASE PROGRESSION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; INFUSIONS, PARENTERAL; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS; NICLOSAMIDE; PROGNOSIS; RANDOM ALLOCATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; S100 PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY; WNT PROTEINS;

EID: 79960263940     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr190     Document Type: Article

References (40)

1. Nelson RS, Thorson AG. Colorectal cancer screening. Curr Oncol Rep. 2009;11(6):482-489.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
3. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003;1653(1):1-24. (Pubitemid 36627817)
4. Stein U, Arlt F, Walther W, et al. The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology. 2006;131(5):1486-1500. (Pubitemid 44708942)
5. Helfman DM, Kim EJ, Lukanidin E, Grigorian M. The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer. 2005;92(11):1955-1958. (Pubitemid 40897415)
6. Kim JH, Kim CN, Kim SY, et al. Enhanced S100A4 protein expression is clinicopathologically significant to metastatic potential and p53 dysfunction in colorectal cancer. Oncol Rep. 2009;22(1):41-47.
7. Gongoll S, Peters G, Mengel M, et al. Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology. 2002;123(5):1478-1484. (Pubitemid 35231647)
8. Ambartsumian NS, Grigorian MS, Larsen IF, et al. Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene. 1996;13(8):1621-1630. (Pubitemid 26377493)
9. Davies MP, Rudland PS, Robertson L, Parry EW, Jolicoeur P, Barraclough R. Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. Oncogene. 1996;13(8):1631-1637. (Pubitemid 26377494)
10. Grum-Schwensen B, Klingelhofer J, Berg CH, et al. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res. 2005;65(9):3772-3780. (Pubitemid 40616355)
11. Boye K, Maelandsmo GM. S100A4 and metastasis: a small actor playing many roles. Am J Pathol. 2010;176(2):528-535.
12. Kriajevska MV, Cardenas MN, Grigorian MS, Ambartsumian NS, Georgiev GP, Lukanidin EM. Non-muscle myosin heavy chain as a possible target for protein encoded by metastasis-related mts-1 gene. J Biol Chem. 1994;269(31):19679-19682. (Pubitemid 24250873)
13. Li ZH, Bresnick AR. The S100A4 metastasis factor regulates cellular motility via a direct interaction with myosin-IIA. Cancer Res. 2006;66(10):5173-5180. (Pubitemid 43844940)
14. Li ZH, Spektor A, Varlamova O, Bresnick AR. Mts1 regulates the assembly of nonmuscle myosin-IIA. Biochemistry. 2003;42(48):14258-14266. (Pubitemid 37499423)
15. Kriajevska M, Fischer-Larsen M, Moertz E, et al. Liprin beta 1, a member of the family of LAR transmembrane tyrosine phosphatase-interacting proteins, is a new target for the metastasis-associated protein S100A4 (Mts1). J Biol Chem. 2002;277(7):5229-5235. (Pubitemid 34975654)
16. Ambartsumian N, Klingelhofer J, Grigorian M, et al. The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor. Oncogene. 2001;20(34):4685-4695. (Pubitemid 32762440)
17. Mathisen B, Lindstad RI, Hansen J, et al. S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis. 2003;20(8):701-711. (Pubitemid 38019272)
18. Saleem M, Kweon MH, Johnson JJ, et al. S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9. Proc Natl Acad Sci USA. 2006;103(40):14825-14830. (Pubitemid 44527813)
19. Yammani RR, Carlson CS, Bresnick AR, Loeser RF. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: role of the receptor for advanced glycation end products. Arthritis Rheum. 2006;54(9):2901-2911. (Pubitemid 44497769)
20. Kim JS, Crooks H, Dracheva T, et al. Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res. 2002;62(10):2744-2748. (Pubitemid 34525754)
21. Hernan R, Fasheh R, Calabrese C, et al. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res. 2003;63(1):140-148. (Pubitemid 36070432)
22. Engelkamp D, Schafer BW, Erne P, Heizmann CW. S100 alpha, CAPL, and CACY: molecular cloning and expression analysis of three calcium-binding proteins from human heart. Biochemistry. 1992;31(42):10258-10264.
23. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 2002;62(15):4316-4324. (Pubitemid 34827288)
24. Sekine S, Shibata T, Sakamoto M, Hirohashi S. Target disruption of the mutant beta-catenin gene in colon cancer cell line HCT116: preservation of its malignant phenotype. Oncogene. 2002;21(38):5906-5911. (Pubitemid 35007241)
25. Sherbet GV. Metastasis promoter S100A4 is a potentially valuable molecular target for cancer therapy. Cancer Lett. 2009;280(1):15-30.
26. Espinosa-Aguirre JJ, Reyes RE, Cortinas de Nava C. Mutagenic activity of 2-chloro-4-nitroaniline and 5-chlorosalicylic acid in Salmonella typhimurium: two possible metabolites of niclosamide. Mutat Res. 1991;264(3):139-145.
27. Kim TH, Kim HI, Soung YH, Shaw LA, Chung J. Integrin (alpha6beta4) signals through Src to increase expression of S100A4, a metastasis-promoting factor: implications for cancer cell invasion. Mol Cancer Res. 2009;7(10):1605-1612.
28. Ganesan K, Ivanova T, Wu Y, et al. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res. 2008;68(11):4277-4286.
29. Andersen K, Smith-Sorensen B, Pedersen KB, et al. Interferon-gamma suppresses S100A4 transcription independently of apoptosis or cell cycle arrest. Br J Cancer. 2003;88(12):1995-2001. (Pubitemid 36829679)
30. Tabata T, Tsukamoto N, Fooladi AA, et al. RNA interference targeting against S100A4 suppresses cell growth and motility and induces apoptosis in human pancreatic cancer cells. Biochem Biophys Res Commun. 2009;390(3):475-480.
31. Hua J, Chen D, Fu H, et al. Short hairpin RNA-mediated inhibition of S100A4 promotes apoptosis and suppresses proliferation of BGC823 gastric cancer cells in vitro and in vivo. Cancer Lett. 2010;292(1):41-47.
32. Jin Y, Lu Z, Ding K, et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-{kappa}B pathway and generation of reactive oxygen species. Cancer Res. 2010;70(6):2516-2527.
33. Balgi AD, Fonseca BD, Donohue E, et al. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One. 2009;4(9):e7124.
34. Chen M, Wang J, Lu J, et al. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry. 2009;48(43):10267-10274.
35. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767.
36. Sack U, Stein U. Wnt up your mind-intervention strategies for S100A4-induced metastasis in colon cancer. Gen Physiol Biophys. 2009;28:F55-F64. Focus Issue.
37. Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science. 2005;307(5717):1904-1909. (Pubitemid 40404692)
38. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006;5(12):997-1014. (Pubitemid 44835127)
39. Merschjohann K, Steverding D. In vitro trypanocidal activity of the anti-helminthic drug niclosamide. Exp Parasitol. 2008;118(4):637-640.
40. Stein U, Burock S, Herrmann P, et al. Diagnostic and prognostic value of metastasis inducer S100A4 transcripts in plasma of colon, rectal, and gastric cancer patients. J Mol Diagn. 2011;13(2):189-198.